<SEC-DOCUMENT>0001193125-22-310169.txt : 20221221
<SEC-HEADER>0001193125-22-310169.hdr.sgml : 20221221
<ACCEPTANCE-DATETIME>20221221172533
ACCESSION NUMBER:		0001193125-22-310169
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20221221
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221221
DATE AS OF CHANGE:		20221221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oric Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001796280
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				471787157
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39269
		FILM NUMBER:		221479190

	BUSINESS ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 388-5600

	MAIL ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d399008d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:oric="http://www.oricpharma.com/20221221" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-12-21_to_2022-12-21">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-12-21_to_2022-12-21">0001796280</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="oric-20221221.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-12-21_to_2022-12-21"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-21</xbrli:startDate> <xbrli:endDate>2022-12-21</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-12-21_to_2022-12-21">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported) <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-12-21_to_2022-12-21" format="ixt:datemonthdayyearen">December 21, 2022</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-12-21_to_2022-12-21">ORIC Pharmaceuticals, Inc.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-12-21_to_2022-12-21" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-12-21_to_2022-12-21">001-39269</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-12-21_to_2022-12-21">47-1787157</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-12-21_to_2022-12-21">240 E. Grand Ave</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-12-21_to_2022-12-21">2<sup style="font-size:75%; vertical-align:top">nd</sup> Floor</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-12-21_to_2022-12-21">South San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-12-21_to_2022-12-21">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-12-21_to_2022-12-21">94080</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-12-21_to_2022-12-21">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-12-21_to_2022-12-21">388-5600</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-12-21_to_2022-12-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-12-21_to_2022-12-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-12-21_to_2022-12-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-12-21_to_2022-12-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-12-21_to_2022-12-21">Common stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-12-21_to_2022-12-21">ORIC</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-12-21_to_2022-12-21" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-12-21_to_2022-12-21" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2022-12-21_to_2022-12-21" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;21, 2022, ORIC Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with Pfizer Inc. (NYSE: PFE) pursuant to which the Company has agreed to sell, and Pfizer Inc. has agreed to purchase, 5,376,344 shares of the Company&#8217;s common stock, $0.0001 par value per share, (the &#8220;Shares&#8221;) at a price of $4.65 per share, for gross proceeds of approximately $25.0&#160;million (the &#8220;Transaction&#8221;). The Shares were offered in a registered direct offering conducted without an underwriter or placement agent and pursuant to an effective shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (Registration <span style="white-space:nowrap">No.&#160;333-255833)</span> (the &#8220;Registration Statement&#8221;), and a prospectus supplement relating to the offer and sale of the Shares was filed with the Securities Exchange Commission (the &#8220;SEC&#8221;). The Transaction is expected to close on or about December&#160;23, 2022, subject to customary closing conditions. A copy of the press release announcing the Transaction is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> (the &#8220;Current Report&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company currently intends to use the net proceeds from the Transaction to fund ongoing and planned clinical trials, including studies of <span style="white-space:nowrap">ORIC-533,</span> <span style="white-space:nowrap">ORIC-114</span> and <span style="white-space:nowrap">ORIC-944,</span> and for working capital and general corporate purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The representations, warranties and covenants contained in the Securities Purchase Agreement were made solely for the benefit of the parties thereto and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Securities Purchase Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Securities Purchase Agreement and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company&#8217;s periodic reports and other filings with the SEC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Securities Purchase Agreement is not complete and is qualified in its entirety by reference to the full text of the Securities Purchase Agreement, a copy of which is filed as Exhibit 99.2 to this Current Report and is incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the opinion of Wilson Sonsini Goodrich&#160;&amp; Rosati, Professional Corporation relating to the legality of the issuance and sale of the Shares offered in the Transaction is attached as Exhibit 5.1 hereto and is incorporated by reference into the Registration Statement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the statements made in this report are forward looking, such as those, among others, relating to the Company&#8217;s expectations regarding the timing and completion of the Transaction. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to completion of the Transaction on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the Transaction. More information about the risks and uncertainties faced by the Company is contained under the caption &#8220;Risk Factors&#8221; in </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the Company&#8217;s Quarterly Report <span style="white-space:nowrap">on&#160;Form&#160;10-Q&#160;filed&#160;with</span> the SEC on November&#160;7, 2022. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in Exhibit 99.1 of this Current Report shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d399008dex51.htm">Opinion of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d399008dex51.htm">Consent of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d399008dex991.htm">Press Release dated December&#160;21, 2022. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d399008dex992.htm">Securities Purchase Agreement. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">ORIC PHARMACEUTICALS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: December&#160;21, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dominic Piscitelli</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Dominic Piscitelli</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d399008dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g399008g1221133513609.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilson Sonsini Goodrich&nbsp;&amp; Rosati <BR>Professional Corporation</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">650 Page Mill Road <BR>Palo Alto, California 94304-1050</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><SMALL>O</SMALL>: 650.493.9300 <BR><SMALL>F</SMALL>: 650.493.6811</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;21, 2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORIC Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">240 E. Grand Avenue, 2nd Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, CA 94080 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel
to ORIC Pharmaceuticals, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the registration of the offer and sale by the Company of 5,376,344 shares (the &#147;<B><I>Shares</I></B>&#148;) of the Company&#146;s
common stock, $0.0001 par value per share, pursuant to the Company&#146;s shelf Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), filed with
the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) on May&nbsp;6, 2021 (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-255833)</FONT> (as so filed and as amended on March&nbsp;22, 2022 and declared
effective as of April&nbsp;27, 2022, the &#147;<B><I>Registration Statement</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering and sale of the Shares are being
made pursuant to the Securities Purchase Agreement, dated as of December 21, 2022, by and between the Company and Pfizer Inc. (the &#147;<B><I>Purchase Agreement</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have examined copies of the Purchase Agreement, the Registration Statement, the base prospectus that forms a part thereof and the
prospectus supplement thereto related to the offering of the Shares, which prospectus supplement is dated as of the date hereof and was filed by the Company in accordance with Rule 424(b) promulgated under the Act. We have also examined instruments,
documents and records which we deemed relevant and necessary for the basis of our opinion hereinafter expressed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In such examination, we
have assumed (i)&nbsp;the authenticity of original documents and the genuineness of all signatures, (ii)&nbsp;the conformity to the originals of all documents submitted to us as copies, and (iii)&nbsp;the truth, accuracy, and completeness of the
information, representations and warranties contained in the records, documents, instruments and certificates we have reviewed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on
and subject to the foregoing, we are of the opinion that the Shares have been duly authorized by the Company and, when issued and delivered by the Company against payment therefor in accordance with the terms of the Purchase Agreement, will be
validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no opinion as to the laws of any other jurisdiction other than the federal laws
of the United States of America and the General Corporation Law of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">AUSTIN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BEIJING&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BOSTON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;BOULDER&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BRUSSELS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HONG KONG &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LONDON &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LOS
ANGELES&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NEW YORK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PALO ALTO </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SALT LAKE CITY
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SAN DIEGO &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SAN FRANCISCO &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SEATTLE &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SHANGHAI
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WASHINGTON, DC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WILMINGTON, DE </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g399008g1221134219834.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORIC Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December 21, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;* </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the use of this opinion as an exhibit to the Company&#146;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> filed on or about December 21, 2022, for incorporation by reference into the Registration Statement and to the use of our name in the prospectus supplement under the caption &#147;Legal Matters.&#148; In giving
such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>WILSON SONSINI GOODRICH&nbsp;&amp; ROSATI </B>Professional Corporation</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d399008dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for <FONT STYLE="white-space:nowrap">ORIC-533</FONT> in
Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>ORIC and Pfizer have entered into a clinical development
collaboration for a Phase 2 study of <FONT STYLE="white-space:nowrap">ORIC-533</FONT> in combination with elranatamab in multiple myeloma </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Jeff Settleman, Ph.D., Chief Scientific Officer, Pfizer Oncology, to join ORIC Scientific Advisory Board </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Including $25&nbsp;million equity investment from Pfizer, ORIC cash runway extended into 1H 2025 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SOUTH SAN FRANCISCO and SAN DIEGO, CA &#150; Dec.&nbsp;21, 2022 &#150;</B> ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical-stage oncology company
focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it has entered into a clinical development collaboration for a potential Phase 2 study of <FONT STYLE="white-space:nowrap">ORIC-533</FONT> in
multiple myeloma with Pfizer and agreed to sell 5,376,344 of its common shares at a price of $4.65 per share to Pfizer for proceeds of approximately $25.0&nbsp;million. The common shares were sold to Pfizer in a registered direct offering conducted
without an underwriter or placement agent. The offering is expected to close on or about December&nbsp;23, 2022, subject to customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORIC and Pfizer have entered into the clinical development collaboration to leverage Pfizer&#146;s global development capabilities and expertise to enhance
the clinical development program for <FONT STYLE="white-space:nowrap">ORIC-533,</FONT> an oral small molecule inhibitor of CD73. Through the agreement, the parties plan to potentially advance <FONT STYLE="white-space:nowrap">ORIC-533</FONT> into a
Phase 2 combination study with elranatamab, Pfizer&#146;s investigational <FONT STYLE="white-space:nowrap">B-cell</FONT> maturation antigen (BCMA) <FONT STYLE="white-space:nowrap">CD3-targeted</FONT> bispecific antibody in development for the
treatment of multiple myeloma. ORIC will maintain full economic ownership and control of <FONT STYLE="white-space:nowrap">ORIC-533.</FONT> In conjunction with the investment, Jeff Settleman, Ph.D., Chief Scientific Officer, Oncology
Research&nbsp;&amp; Development, Pfizer, will join ORIC&#146;s Scientific Advisory Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We continue to be encouraged by the potential of <FONT
STYLE="white-space:nowrap">ORIC-533</FONT> as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> treatment for patients with multiple myeloma, and a natural next step is to explore <FONT
STYLE="white-space:nowrap">ORIC-533</FONT> in combination with approved and emerging therapies, including BCMA directed therapies,&#148; said Jacob M. Chacko, M.D., chief executive officer. &#147;Given Pfizer&#146;s strong commitment, extensive
capabilities and deep expertise in developing treatments for oncology, including elranatamab in multiple myeloma, we are proud to partner with them to develop a potential novel treatment regimen for patients with multiple myeloma. We look forward to
realizing the full potential of <FONT STYLE="white-space:nowrap">ORIC-533</FONT> and continuing to advance our promising pipeline.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are
excited to support the clinical development of <FONT STYLE="white-space:nowrap">ORIC-533,</FONT> which represents a novel mechanism in multiple myeloma and a promising product candidate to combine with elranatamab,&#148; said Dr.&nbsp;Settleman.
&#147;Given the high unmet need for patients with multiple myeloma and potential for relapse, we believe new treatments and combinations with novel mechanisms of action that counter mechanisms leading to resistance are essential to improving
outcomes. We are encouraged by the potential of <FONT STYLE="white-space:nowrap">ORIC-533</FONT> and, through our relationship with ORIC, look forward to continuing to work toward improving the lives of people with cancer.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORIC intends to use the proceeds from the offering to fund ongoing and planned clinical trials, including
studies of <FONT STYLE="white-space:nowrap">ORIC-533;</FONT> <FONT STYLE="white-space:nowrap">ORIC-114,</FONT> its brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations; and <FONT
STYLE="white-space:nowrap">ORIC-944,</FONT> an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer; and for working capital and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Including Pfizer&#146;s equity investment, ORIC expects its cash runway to be extended into the first half of 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above were offered by means of a prospectus supplement dated December&nbsp;21, 2022, and accompanying prospectus dated April&nbsp;27,
2022, forming a part of the Company&#146;s effective shelf registration statement (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-255833).</FONT> The prospectus supplement and accompanying prospectus relating to this offering will be filed with
the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) and will be available on the SEC&#146;s website at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release
shall not constitute an offer to sell or the solicitation of an offer to buy the common shares, nor shall there be any sale of the common shares in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any such state or other jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ORIC Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients&#146; lives by<I> Overcoming</I><I></I><I>
Resistance</I><I></I><I> In</I><I></I><I> Cancer.</I><I></I> ORIC&#146;s clinical stage product candidates include <FONT STYLE="white-space:nowrap">(1)&nbsp;ORIC-533,</FONT> an orally bioavailable small molecule inhibitor of CD73, a key node in the
adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, <FONT STYLE="white-space:nowrap">(2)&nbsp;ORIC-114,</FONT> a brain penetrant inhibitor
designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and <FONT STYLE="white-space:nowrap">(3)&nbsp;ORIC-944,</FONT> an allosteric inhibitor
of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms.
ORIC has offices in South San Francisco and San Diego, California. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements as that term is defined in Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the
Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential benefits of and activity
under the clinical development collaboration between&nbsp;ORIC and Pfizer; ORIC&#146;s development plans for <FONT STYLE="white-space:nowrap">ORIC-533;</FONT> the potential advantages of ORIC&#146;s product candidates and programs; ORIC&#146;s cash
runway; the expected timing of the closing of the sale of shares to Pfizer; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the intended use of proceeds from such offering; and statements by the company&#146;s chief executive officer and Dr.&nbsp;Settleman. Words such as &#147;believes,&#148; &#147;anticipates,&#148;
&#147;plans,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;will,&#148; &#147;goal,&#148; &#147;potential&#148; and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are
based upon ORIC&#146;s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and
uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company;
ORIC&#146;s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC&#146;s plans to develop and commercialize its product candidates,
including without limitation, in the event the data from the ongoing Phase 1b trial of <FONT STYLE="white-space:nowrap">ORIC-533</FONT> does not support advancement into a Phase 2 study; the potential for clinical trials of <FONT
STYLE="white-space:nowrap">ORIC-533,</FONT> <FONT STYLE="white-space:nowrap">ORIC-114,</FONT> <FONT STYLE="white-space:nowrap">ORIC-944</FONT> or any other product candidates to differ from preclinical, initial, interim, preliminary or expected
results; negative impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on ORIC&#146;s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the
termination of the agreements and transactions with Pfizer; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC&#146;s license agreements; ORIC&#146;s ability to raise any additional
funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC&#146;s reliance on third parties, including Pfizer, contract manufacturers and contract
research organizations; ORIC&#146;s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic
and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled &#147;Risk Factors&#148; in ORIC&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed
with the Securities and Exchange Commission (the &#147;SEC&#148;) on November&nbsp;7, 2022, and ORIC&#146;s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no
obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dominic Piscitelli, Chief Financial Officer
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">dominic.piscitelli@oricpharma.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">info@oricpharma.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>d399008dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Securities Purchase Agreement (this &#147;<U>Agreement</U>&#148;) is dated as of December 21, 2022, between ORIC Pharmaceuticals, Inc., a
corporation organized under the laws of the State of Delaware (the &#147;<U>Company</U>&#148;), and Pfizer Inc., a corporation organized under the laws of the State of Delaware (the &#147;<U>Purchaser</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the
Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), the Company desires to issue and sell to the Purchaser, and the Purchaser desires to purchase from the Company, shares of the Company&#146;s common stock as more fully
described in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, concurrently herewith, the Company and the Purchaser have entered into an Information Rights
Agreement and the Company and the Purchaser have entered into a Development Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, IN CONSIDERATION</B> of the
mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DEFINITIONS
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following
terms have the meanings set forth in this <U>Section</U><U></U><U>&nbsp;1.1</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Action</U>&#148; shall have the meaning
ascribed to such term in <U>Section</U><U></U><U>&nbsp;3.1(l)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means any Person that, directly or
indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Base Prospectus</U>&#148; means the final base prospectus included in the Registration Statement at the time of effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Board of Directors</U>&#148; means the board of directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States
or any day on which the Trading Market and banking institutions in the State of New York are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing</U>&#148; means the closing of the purchase and sale of Purchased Shares pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; means the Trading Day on which all conditions precedent to (i)&nbsp;the Purchaser&#146;s obligations to
pay the Subscription Amount and (ii)&nbsp;the Company&#146;s obligations to deliver the Purchased Shares, in each case, have been satisfied or waived, but in no event later than the second (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP>)
Trading Day following the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commission</U>&#148; means the United States Securities and Exchange Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Shares</U>&#148; means the shares of the Company&#146;s common stock, par
value $0.0001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Data Security Obligations</U>&#148; shall have the meaning ascribed to such term in <U>Section</U><U></U><U>&nbsp;3.1(kk)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosure Time</U>&#148; means, (i)&nbsp;if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York
City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, and (ii)&nbsp;if this Agreement is signed between midnight (New York City time) and 9:00
a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental
Laws</U>&#148; shall have the meaning ascribed to such term in <U>Section</U><U></U><U>&nbsp;3.1(o)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FCPA</U>&#148;
means the Foreign Corrupt Practices Act of 1977, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; means the U.S. Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means U.S. generally accepted accounting principles applied on a consistent basis during the periods involved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Global Trade Laws and Regulations</U>&#148; means the U.S. Export Administration Regulations; the U.S. International Traffic in Arms
Regulations; the import laws administered by U.S. Customs and Border Protection; the economic sanctions rules and regulations administered by OFAC; the anti-boycott laws and regulations administered by the U.S. Departments of Commerce and Treasury;
the UK Export Control Act 2002; UK Export Control Order 2008/3231; EU Council Regulation 428/2009 (as maintained by the European Union or retained by the United Kingdom); EU Council sanctions regulations, as implemented in EU Member States;
sanctions regimes implemented under the UK Sanctions and Anti-Money Laundering Act 2018; Canadian sanctions policies; United Nations sanctions policies; and all relevant regulations made under any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Health Care Laws</U>&#148; shall have the meaning ascribed to such term in <U>Section</U><U></U><U>&nbsp;3.1(ff).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>HIPAA</U>&#148; shall have the meaning ascribed to such term in <U>Section</U><U></U><U>&nbsp;3.1(ff)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property</U>&#148; shall have the meaning ascribed to such term in <U>Section</U><U></U><U>&nbsp;3.1(r)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liens</U>&#148; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other
restriction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Adverse Effect</U>&#148; shall have the meaning assigned to such term in
<U>Section</U><U></U><U>&nbsp;3.1(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Permits</U>&#148; shall have the meaning ascribed to such term in
<U>Section</U><U></U><U>&nbsp;3.1(p)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Money Laundering Laws</U>&#148; shall have the meaning ascribed to such term in
<U>Section</U><U></U><U>&nbsp;3.1(jj).</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Per Share Purchase Price</U>&#148; equals $4.65 subject to adjustment for reverse and
forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Shares that occur after the date of this Agreement and prior to Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means an individual or corporation, partnership, trust,
incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Preferred Shares</U>&#148; means the shares in the Company&#146;s preferred stock, par value $0.0001 per share, issuable in series.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Proceeding</U>&#148; means an action, claim, suit, investigation or proceeding (including, without limitation, an informal
investigation or partial proceeding, such as a deposition), whether commenced or threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Prospectus Supplement</U>&#148;
means the supplement to the Base Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission and delivered by the Company to the Purchaser on or prior to Closing, relating to the offer and sale of the Purchased
Shares to the Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchased Shares</U>&#148; means 5,376,344 Common Shares issuable to the Purchaser pursuant to this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Statement</U>&#148; means the effective registration statement on Form
<FONT STYLE="white-space:nowrap">S-3ASR</FONT> filed with the Commission (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-255833)</FONT> pursuant to the Securities Act on May&nbsp;6, 2021, which became effective automatically upon its filing,
relating to the offer and sale from time to time of the Company&#146;s securities, including the Purchased Shares, including amendments, exhibits, schedules and documents incorporated or deemed to be incorporated by reference therein and the
documents otherwise deemed to a part thereof pursuant to Rule 430A or 430B under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Representative</U>&#148;
means as to any person, its directors, officers, employees, agents and advisors (including, without limitation, financial advisors, attorneys and accountants) and debt and/or equity financing sources and their advisors<U>.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Required Approvals</U>&#148; shall have the meaning ascribed to such term in <U>Section</U><U></U><U>&nbsp;3.1(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rule 424</U>&#148; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or
interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sanctioned Countries</U>&#148; shall have the meaning ascribed to such term in <U>Section</U><U></U><U>&nbsp;3.1(ii).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sanctions</U>&#148; shall have the meaning ascribed to such term in <U>Section</U><U></U><U>&nbsp;3.1(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC Reports</U>&#148; shall have the meaning ascribed to such term in <U>Section</U><U></U><U>&nbsp;3.1(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Short Sales</U>&#148; means all &#147;short sales&#148; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing Common Shares). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subscription Amount</U>&#148; means the aggregate amount to
be paid by the Purchaser to the Company for the Purchased Shares pursuant to the terms and conditions of this Agreement calculated by multiplying the number of Purchased Shares by the Per Share Purchase Price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Day</U>&#148; means a day on which the principal Trading Market is open for
trading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Market</U>&#148; means The Nasdaq Global Select Market (or any successors thereto). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer Agent</U>&#148; means Computershare Trust Company, N.A., and any successor transfer agent of the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PURCHASE AND
SALE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell,
and the Purchaser agrees to purchase, the Purchased Shares at the Per Share Purchase Price. The Subscription Amount shall be made available for &#147;Delivery Versus Payment&#148; settlement with the Company or its designee. The Company and the
Purchaser shall deliver the items set forth in <U>Section</U><U></U><U>&nbsp;2.2 </U>deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in <U>Section</U><U></U><U>&nbsp;2.2</U> and
<U>Section</U><U></U><U>&nbsp;2.3</U>, the Closing shall occur remotely or at such physical location as the parties shall mutually agree. Payment of the Subscription Amount for the Purchased Shares shall be made by the Purchaser to the Company by
wire transfer of immediately available funds to a bank account designated by the Company against delivery to the Purchaser of the Purchased Shares registered in the Purchaser&#146;s name and address or as otherwise directed to be registered by the
Purchaser, including but not limited to delivery through the facilities of The Depository Trust Company Deposit or Withdrawal at Custodian system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Deliveries</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchaser the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) this Agreement duly
executed by the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the Prospectus Supplement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) a copy of the executed treasury direction to the Transfer Agent instructing the Transfer Agent to deliver the Purchased Shares,
registered in the name of the Purchaser or such other registration information as directed by the Purchaser; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) a certificate, dated
the Closing Date, signed by an executive officer of the Company (in his or her capacity as an officer and without personal liability), certifying the matters in <U>Sections 2.3(b)(i)</U> and <U>2.3(b)(ii)</U> below; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) a certificate of the secretary of the Company dated as of the Closing Date certifying that (1)&nbsp;attached thereto is a true and
complete copy of each of the Company&#146;s constating documents and all resolutions adopted by the Board of Directors of the Company authorizing the execution, delivery and performance of this Agreement and that all such documents and resolutions
are in full force and effect and (2)&nbsp;the incumbency of each officer signing this Agreement and the certificates and the documents to be delivered hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) the Company&#146;s wire instructions, on Company letterhead and signed by the Chief Executive Officer or Chief Financial Officer of the
Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) a certificate of good standing of the Company, dated within one (1)&nbsp;Business Day of the Closing Date, in form and
substance reasonably satisfactory to the Purchaser; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) a customary opinion of the Company&#146;s outside legal counsel, dated the Closing
Date, relating to the Purchased Shares, in form and substance reasonably satisfactory to the Purchaser; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) the Purchased Shares
(subject to receipt of the Subscription Amount). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) On or prior to the Closing Date, the Purchaser shall deliver or cause to be
delivered to the Company, the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) this Agreement duly executed by the Purchaser; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the Subscription Amount, with respect to the Purchased Shares purchased by the Purchaser, which shall be made available for
&#147;Delivery Versus Payment&#148; settlement with the Company or its designee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Closing Conditions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) on the Closing Date of the representations and warranties of the Purchaser contained herein (unless as of a specific date therein in which case they shall be accurate as of such date); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) all obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the delivery by the Purchaser of the items set forth in <U>Section</U><U></U><U>&nbsp;2.2(b)</U> of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being met: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate as of such date); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been
performed; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the delivery by the Company of the items set forth in <U>Section</U><U></U><U>&nbsp;2.2(a)</U> of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) there shall have been no Material Adverse Effect with respect to the Company since the date hereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) no stop order or cease trade order suspending the effectiveness of the Registration Statement or any part thereof, preventing or
suspending the use of the Base Prospectus or the Prospectus Supplement or any part thereof shall have been issued, and no proceedings for that purpose shall have been initiated or threatened; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) from the date hereof to the Closing Date, trading in the Common Shares shall not have
been suspended by the Commission or the Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been
established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material
outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of the Purchaser, makes it
impracticable or inadvisable to purchase the Purchased Shares at the Closing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REPRESENTATIONS AND WARRANTIES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Representations and Warranties of the Company</U>. The Company hereby represents and warrants as of the date hereof and as of the
Closing Date to the Purchaser as follows (unless as of a specific date therein, in which case they shall be accurate as of such date): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Subsidiaries</U>. The<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>Company does not own, directly or indirectly, any shares of
stock or any other equity or long-term debt securities of any corporation or have any equity interest in any corporation, firm, partnership, joint venture, association or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Organization and Qualification</U>. The Company is an entity duly incorporated or otherwise organized, validly existing and in good
standing (to the extent the concept of good standing is applicable in such jurisdiction) under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to
carry on its business as currently conducted and as described in each of the Registration Statement, and the Prospectus Supplement. The Company is not in violation or default of any of the provisions of its certificate of incorporation or bylaws,
except where such violation or default would not reasonably be expected to have a Material Adverse Effect. The Company is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in
which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have resulted or reasonably be expected to result
in: (i)&nbsp;a material adverse effect on the legality, validity or enforceability of this Agreement, (ii)&nbsp;a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company,
or (iii)&nbsp;a material adverse effect on the Company&#146;s ability to perform on a timely basis its obligations under this Agreement (any of (i), (ii) or (iii), a &#147;<U>Material Adverse Effect</U>&#148;) and no Proceeding has been instituted
in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the
transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly
authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&#146;s stockholders in connection herewith other than in connection with the Required Approvals.
This Agreement has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the
Company in accordance with its terms, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#146; rights
generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>No Conflicts</U>. The execution, delivery and performance by the Company of this
Agreement, the issuance and sale of the Purchased Shares and the consummation by it of the transactions contemplated hereby do not and will not (i)&nbsp;conflict with or violate any provision of the Company&#146;s certificate of incorporation or
bylaws, or (ii)&nbsp;contravene or constitute a default (or an event that with notice or lapse of time or both would become a default) under any agreement or other instrument binding upon the Company that is material to the Company, or result in the
creation of any Lien upon any of the properties or assets of the Company or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both), or
(iii)&nbsp;subject to the Required Approvals, conflict with or result in a violation of any applicable law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is
subject (including federal, and state securities laws and regulations), or by which any property or asset of the Company is bound or affected; except in the case of each of clauses (ii)&nbsp;and (iii), such as would not have or reasonably be
expected to result in a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Filings, Consents and Approvals</U>. The Company is not required to obtain any
consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority, or the Financial Industry Regulatory Authority, or other Person in
connection with the execution, delivery and performance by the Company of this Agreement, other than: (i)&nbsp;the filings required pursuant to <U>Section</U><U></U><U>&nbsp;4.2</U> of this Agreement, (ii)&nbsp;the filing with the Commission of the
Prospectus Supplement, (iii)&nbsp;application(s) to each applicable Trading Market for approval for the listing of the Purchased Shares for trading thereon in the time and manner required thereby, and (iv)&nbsp;such filings as are required to be
made under applicable state securities laws (collectively, the &#147;<U>Required Approvals</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Issuance of the Purchased
Shares; Registration</U>. The Purchased Shares are duly authorized and, when issued and paid for in accordance with this Agreement, will be duly and validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> free and
clear of all Liens. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, including the Base Prospectus, and such amendments and supplements thereto as may have been required to the
date of this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus Supplement has
been issued by the Commission and no proceedings for that purpose or pursuant to Section&nbsp;8A under the Securities Act have been instituted or, to the knowledge of the Company, are threatened by the Commission. Promptly after execution and
delivery of this Agreement, the Company shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b) within the time period required under Rule 424(b), and in no event later than the Closing Date. At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the
Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus Supplement and
any amendments or supplements thereto, as of the date of the Prospectus Supplement or any amendment or supplement thereto and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and the
applicable rules and regulations of the Commissions thereunder and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The Company was at the time of the filing of the Registration Statement and is, as of the date of this Agreement and the Closing, eligible to use a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Listing.</U> The Company has filed a Listing of Additional Shares Notification with
the Trading Market with respect to the Purchased Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Capitalization</U>. The capitalization of the Company is as set forth in
the SEC Reports. The Company has not issued any securities since its most recently filed audited financial statements, other than pursuant to the exercise of outstanding employee stock options under the Company&#146;s stock option plans, the
issuance of securities to employees pursuant to the Company&#146;s 2020 Equity Incentive Plan, the Company&#146;s 2014 Equity Incentive Plan, as amended, the Company&#146;s 2020 Employee Stock Purchase Plan and the Company&#146;s 2022 Inducement
Equity Incentive Plan. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by this Agreement. Except as a set forth in the SEC Reports or would not
reasonably be expected to have a Material Adverse Effect, there are no outstanding options, warrants, subscription rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any Common Shares, Preferred Shares or other securities of the Company, or contracts, commitments, understandings or arrangements by which the
Company is or may become bound to issue additional Common Shares, any Preferred Shares or other securities of the Company. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable,</FONT> have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or
purchase securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and
other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a) or 15(d) thereof, for the two years preceding the date hereof (the foregoing materials, including the
exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the &#147;<U>SEC Reports</U>&#148;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC
Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when
filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading. The financial statements of the Company (or any predecessor entity thereof) included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect
thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with GAAP, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in
the case of unaudited statements, to normal, immaterial, <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)
<U>Company Not Ineligible Issuer</U>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or another offering participant made a bona fide offer (within the
meaning of Rule 164(h)(2) of the Securities Act) of the Purchased Shares and at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rules 164, 405, and 433 under the Securities Act (without taking account
of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ineligible issuer). Any free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance
with the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or
that was prepared by or on behalf of or used or referred to by the Company complies or will comply, as of the date of such filing, in all material respects with the applicable requirements of the Securities Act and the applicable rules and
regulations of the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of
the latest audited financial statements included within the SEC Reports, (i)&nbsp;there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii)&nbsp;the Company has
not incurred any material liabilities (contingent or otherwise) other than (A)&nbsp;trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B)&nbsp;liabilities not required to be reflected
in the Company&#146;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii)&nbsp;the Company has not altered its method of accounting, (iv)&nbsp;the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v)&nbsp;the Company has not issued any equity securities to any officer, director or
Affiliate, except pursuant to existing Company equity incentive plans. Except for the issuance of the Purchased Shares contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is
reasonably expected to occur or exist with respect to the Company or its business, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time
this representation is made or deemed made that has not been publicly disclosed prior to the date that this representation is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)
<U>Litigation</U>. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its properties before or by any court,
arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#147;<U>Action</U>&#148;) which (i)&nbsp;adversely affects or challenges the legality, validity or enforceability
of this Agreement or the issuance and sale of the Purchased Shares or (ii)&nbsp;could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any director or officer
thereof is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. Except as set forth in the SEC Reports, there has not been, and to the
knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) <U>Absence of Labor Disputes</U>. No labor dispute with the employees of the Company exists or, to the knowledge of the Company, is
imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers, customers or contractors, which, in either case, would result in a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) <U>Compliance</U>. Upon the execution and delivery by the Company of, and the performance by the Company of its obligations under, this
Agreement, the Company will not be: (i)&nbsp;in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company under) any indenture, loan or
credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) in violation of any judgment, decree or order of any
court, arbitrator or other governmental authority or (iii)&nbsp;in violation of any statute, rule, ordinance, regulation or guidance of any governmental authority, including without limitation all foreign, federal, state and local laws relating to
taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) <U>Environmental Laws</U>. The Company (i)&nbsp;is in compliance with any and all
applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#147;<U>Environmental Laws</U>&#148;),
(ii) has received all permits, licenses or other approvals required of it under applicable Environmental Laws to conduct its business and (iii)&nbsp;is in compliance with all terms and conditions of any such permit, license or approval, except where
such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, reasonably
be expected to have a Material Adverse Effect. There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for <FONT STYLE="white-space:nowrap">clean-up,</FONT>
closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, reasonably be
expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) <U>Regulatory Permits</U>. The Company has possessed and currently possesses all
certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct its business as described in the SEC Reports, except where the failure to possess such permits could not
reasonably be expected to result in a Material Adverse Effect (&#147;<U>Material Permits</U>&#148;), and the Company has not received any notice of proceedings relating to the revocation or restriction of any Material Permit. All Material Permits
are in full force and effect and the Company is not in violation of any term or condition thereof except violations which could not reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) <U>Title to Assets</U>. The Company does not own any real property. The Company has good and marketable title to all personal property
(other than intellectual property, which is addressed exclusively in <U>Section</U><U></U><U>&nbsp;3.1(r)</U> below) owned by it that is material to the business of the Company, in each case free and clear of all Liens, except for Liens as do not
materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company. Any real property and facilities held under lease by the Company are held by it under valid,
subsisting and enforceable leases with which the Company is in compliance and with such exceptions as are not material and would not reasonably be expected to materially interfere with the use made and proposed to be made of such property and
buildings by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) <U>Intellectual Property</U>. (i)&nbsp;the Company owns or possesses valid and enforceable license rights
or other rights to use, all material patents, patent applications, inventions, copyrights, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks,
service marks, and trade names, (collectively, the &#147;<U>Intellectual Property</U>&#148;) necessary for the conduct of the Company&#146;s business as currently conducted by the Company or as necessary for the business as proposed to be conducted,
in each case as described in the SEC Reports, except where the failure to own, possess or license such rights would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (ii)&nbsp;the Intellectual Property
of the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
part; (iii)&nbsp;except with respect to the prosecution of patent applications within the Intellectual Property occurring before national and regional patent offices in the normal course of
business, there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity, scope or enforceability of any such Intellectual Property; (iv)&nbsp;except as disclosed in the SEC
Reports, the Company has not received any notice (written or otherwise) alleging any infringement, misappropriation or other violation of intellectual property rights of others; (v)&nbsp;except as would not, individually or in the aggregate, be
reasonably expected to have a Material Adverse Effect, to the Company&#146;s knowledge, no third party is infringing, misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated, any Intellectual Property owned
by the Company; (vi)&nbsp;to the Company&#146;s knowledge, all employees, and contractors with whom the Company has a direct contractual relationship, that are engaged in the development of Intellectual Property which is material to the business of
the Company as currently conducted by the Company or as necessary for the business as proposed to be conducted, in each case as described in the SEC Reports, have executed an invention assignment agreement whereby such employees and contractors
presently assign all of their right, title and interest in and to such Intellectual Property to the Company, and to the Company&#146;s knowledge, no such agreement has been breached or violated; and (vii)&nbsp;to the Company&#146;s knowledge, all
employees and subcontractors of any contractor with whom the Company has a direct contractual relationship have executed an invention assignment agreement whereby such employees and subcontractors of such contractor with whom the Company has a
direct contractual relationship have assigned and presently assign all of their right, title and interest in and to such Intellectual Property to such contractors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) <U>Insurance</U><I>.</I> The Company carries or is entitled to the benefits of insurance, with financially sound and reputable insurers,
in such amounts and covering such risks as in the Company&#146;s reasonable judgment are customary in the business in which it is engaged, and all such insurance is in full force and effect. The Company has no reason to believe that it will not be
able (i)&nbsp;to renew its existing insurance coverage as and when such policies expire or (ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost
that would not, singly or in the aggregate, result in a Material Adverse Effect. The Company has not been denied any insurance coverage which it has sought or for which it has applied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) <U>Transactions With Affiliates and Employees</U>. There are no business relationships or related-party transactions involving the Company
or any other Person required by the Securities Act to be described in the Prospectus Supplement or otherwise in the SEC Reports that have not been described as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) <U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company is in compliance with any and all applicable requirements of the
Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company maintains
a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations, (ii)&nbsp;transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization, and (iv)&nbsp;the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has established disclosure controls and procedures (as defined in Exchange Act Rules <FONT
STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> for the Company and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports
it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#146;s rules and forms. Since the end of the Company&#146;s most recent audited fiscal year, there has
been (1)&nbsp;no material weakness in the Company&#146;s internal control over financial reporting (whether or not remediated) and (2)&nbsp;no change in the Company&#146;s internal control over financial reporting that has a Material Adverse Effect,
or is reasonably likely to have a Material Adverse Effect on the Company&#146;s internal control over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) <U>Certain Fees</U>. No brokerage or finder&#146;s fees or commissions are or will be
payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w) <U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Common Shares,
will not be or be an Affiliate of, an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) <U>Registration Rights</U>. No Person has any right to cause the Company to effect the registration under the Securities Act of any
securities of the Company, except as otherwise have been validly waived in connection with the filing of the Registration Statement or the Prospectus Supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y) <U>Listing and Maintenance Requirements</U>. The Common Shares are registered pursuant to Section&nbsp;12(b) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Shares under the Exchange Act nor has the Company received any notification that the Commission is
contemplating terminating such registration. The Company has not, at any time since April&nbsp;23, 2020, received notice from any Trading Market on which the Common Shares is or has been listed or quoted to the effect that the Company is not in
compliance with the listing or maintenance requirements of such Trading Market. The Company is, and at all times since April&nbsp;23, 2020 has been, and has no reason to believe that it will not in the foreseeable future continue to be, in
compliance with all such listing and maintenance requirements. The Common Shares are currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of
the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(z) <U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by this Agreement, the
Company confirms that neither it nor any other Person acting on its behalf has provided the Purchaser or its agents or counsel with any information that it believes constitutes or might constitute material,
<FONT STYLE="white-space:nowrap">non-public</FONT> information that is not otherwise disclosed in the Prospectus Supplement or the SEC Reports. The Company understands and confirms that the Purchaser will rely on the foregoing representation in
effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchaser regarding the Company, its business and the transactions contemplated hereby, is true and correct and does not
contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The Company acknowledges and
agrees that the Purchaser makes or has made no representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in <U>Section</U><U></U><U>&nbsp;3.2 </U>hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(aa) <U>Payment of Taxes</U>. All federal, state, local and foreign income tax returns of the Company required by law to be filed have been
filed and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid (except for such failure to file or pay as would not, singly or in the aggregate, result in a Material Adverse Effect), except assessments
against which appeals have been or will be promptly taken and as to which adequate reserves have been provided. The Company has filed all other tax returns that are required to have been filed by it pursuant to applicable foreign, state, local or
other law except insofar as the failure to file such returns would not, singly or in the aggregate, result in a Material Adverse Effect, and have paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company
(except as would not, singly or in the aggregate, result in a Material Adverse Effect), except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been established by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(bb) <U>Foreign Corrupt Practices</U>. Neither the Company, nor to the knowledge of the
Company, any Affiliate, director, officer, employee, agent or other person acting on behalf of the Company, has (i)&nbsp;directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to
foreign or domestic political activity, (ii)&nbsp;made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii)&nbsp;failed to disclose
fully any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) that is in violation of law, (iv)&nbsp;violated in any material respect any provision of FCPA; or (v)&nbsp;taken or will take any
action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official (including any officer
or employee of a government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or
candidate for political office) in order to influence official action of such government official, inducing such government official to do or omit to do an act in violation of his or her official duty, or to secure any improper advantage, or to any
person in violation of any applicable anti-corruption laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(cc) <U>Accountants</U>. The Company&#146;s accountants<B> </B>who certified
the financial statements and supporting schedules included or incorporated by reference in the Registration Statement, the Prospectus Supplement or otherwise in the SEC Reports is an independent registered public accountant firm within the meaning
of the Securities Act and the applicable rules and regulations thereunder adopted by the Commission and the Public Company Accounting Oversight Board (United States) with respect to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(dd) <U>Acknowledgment Regarding Purchaser&#146;s Purchase of Securities</U>. The Company acknowledges and agrees that the Purchaser is acting
solely in the capacity of an arm&#146;s length purchaser with respect to this Agreement and the transactions contemplated hereby. The Company further acknowledges that the Purchaser is not acting as a financial advisor or fiduciary of the Company
(or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any advice given by the Purchaser or any of their respective Representatives or agents in connection with this Agreement and the transactions
contemplated hereby is merely incidental to the Purchaser&#146;s purchase of the Purchased Shares. The Company further represents to the Purchaser that the Company&#146;s decision to enter into this Agreement has been based solely on the independent
evaluation of the transactions contemplated hereby by the Company and its Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ee) <U>Regulation M Compliance</U>. The
Company has not, and to its knowledge no one acting on its behalf has taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company in a violation of
Regulation M under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ff) <U>FDA Compliance</U>. Except as would not reasonably be expected to have a Material Adverse
Effect, the Company has operated at all times since January&nbsp;1, 2017 and is currently in compliance with all applicable statutes, rules and regulations of the FDA and comparable regulatory authorities, as applicable, including, as applicable:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Federal Food, Drug, and Cosmetic Act and the regulations promulgated thereunder; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) all applicable federal, state, local and foreign health care laws, including, without
limitation, the U.S. Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil Monetary Penalties Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the U.S. Civil False
Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), all applicable federal, state, local and all foreign criminal laws relating to health care fraud and abuse, including but not limited to the U.S. False Statements Law (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18 U.S.C. Sections 286 and 287, and, as applicable, the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996
(&#147;<U>HIPAA</U>&#148;) (42 U.S.C. Section&nbsp;1320d et seq.), the U.S. Physician Payments Sunshine Act (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7h),</FONT> the exclusion law (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the statutes, regulations and directives of applicable government funded or sponsored healthcare programs, and the regulations promulgated pursuant to such statutes; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) HIPAA, the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.), and the
regulations promulgated thereunder and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof or any other law or regulation the purpose of which is to protect the privacy of individuals or prescribers; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company and the
ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the
Company; (clauses (i)&nbsp;through (iv), to the extent applicable to the Company and its business as currently conducted or as necessary for the business as proposed to be conducted, in each case as described in the SEC Reports, collectively,
&#147;<U>Health Care Laws</U>&#148;; provided that Health Care Laws exclude Data Security Obligations, which are subject to representations in Section&nbsp;3.1(kk)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(gg) <U>Studies</U>. (i)&nbsp;The studies, tests and preclinical and clinical trials conducted by the Company that are described in the SEC
Reports were, and if still pending are, being conducted in all material respects in accordance with applicable Health Care Laws, (ii)&nbsp;the Company has no knowledge of any other studies or trials, the results of which the Company reasonably
believes are materially inconsistent with the results described or referred to in the SEC Reports when viewed in the context in which such results are described and the clinical state of development; (iii)&nbsp;the Company has not received any
written notices, correspondence or other communications from any Regulatory Authority or any other governmental entity requiring or, to the knowledge of the Company, threatening the termination or suspension of any studies or trials that are
described in the SEC Reports or the results of which are referred to in the SEC Reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(hh) <U>Research</U>. Neither the Company, nor
any of its officers or directors, nor, to the Company&#146;s knowledge any of its employees, agents or clinical investigators, has been excluded, suspended disqualified or debarred by FDA, from participation in any U.S. federal health care program,
from participation in human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding or other similar action that would reasonably be expected to result in debarment, disqualification,
suspension or exclusion or convicted of any crime or engaged in any conduct that would reasonably be expected to result in debarment under 21 U.S.C. &#167; 335a, or similar adverse event under comparable foreign laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U>Sanctions</U>. Neither the Company nor, to the Company&#146;s knowledge, any
director, officer, agent, employee or Affiliate of the Company is an individual or entity that is, or is owned or controlled by one or more Persons that are: (i)&nbsp;currently the target of any sanctions administered or enforced by the U.S.
government, including without limitation by the Office of Foreign Assets Control of the U.S. Treasury Department, the United Nations Security Council, the European Union, or Her Majesty&#146;s Treasury, including, designation on OFAC&#146;s
Specially Designated Nationals and Blocked Persons List; and the consolidated list of Persons, Groups and Entities subject to EU Financial Sanctions, as implemented by the EU Common Foreign&nbsp;&amp; Security Policy (collectively,
&#147;<U>Sanctions</U>&#148;), (ii) the subject of current, pending, or, to the Company&#146;s knowledge, threatened investigation, inquiry or enforcement proceedings for violations of Global Trade Laws and Regulations, or have violated or received
any written notice, request, or citation for any actual or potential noncompliance with Global Trade Laws and Regulations; or (iii)&nbsp;is located, organized or resident in a country or territory that is the subject of country-wide or
territory-wide Sanctions (as of the date of this Agreement, Cuba, Iran, North Korea, Syria the Crimea region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic region of Ukraine, and the <FONT
STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic region of Ukraine) (&#147;<U>Sanctioned Countries</U>&#148;). The Company will not directly or knowingly indirectly use the proceeds of the sale of the Purchased Shares, or
knowingly lend, contribute or otherwise make available such proceeds to any joint venture partners or other Person, to fund or facilitate any activities of or business with any Person, or in any country or territory, that, at the time of such
funding, is the subject of comprehensive Sanctions, in violation of Sanctions, or in any other manner that will result in a violation by any Person (including any Person participating in the transactions contemplated hereby, whether as an agent,
advisor, investor or otherwise) of Sanctions. The Company has not knowingly engaged in, is not now knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the
dealing or transaction is or was the subject of comprehensive Sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(jj) <U>Money Laundering</U>. The operations of the Company are
and have been conducted at all times in material compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the Bank Secrecy Act as amended by Title III
of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable money laundering statutes and the applicable rules and regulations of
jurisdictions where the Company conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency thereunder (collectively, the
&#147;<U>Money Laundering Laws</U>&#148;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge
of the Company, threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(kk) <U>Privacy Laws</U>. Except to the extent that any noncompliance would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect, the Company has complied and is presently in compliance with all internal policies, contractual obligations, applicable laws or statutes, and judgments, orders, rules and
regulations of any court or arbitrator or other governmental or regulatory authority relating to the collection, use, transfer, import, export, storage, protection, disposal and disclosure by the Company of personally identifiable or other regulated
data (&#147;<U>Data Security Obligations</U>&#148;); (ii) the Company has not received any written notification of or complaint regarding material <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligations; and
(iii)&nbsp;there is no action, suit or proceeding by or before any court or governmental agency, authority or body pending or, to the Company&#146;s knowledge, threatened alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data
Security Obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ll) <U>Statements</U>. Neither the Company nor any of its officers, employees or agents has made any untrue
statement of a material fact or fraudulent statement to any governmental authority or failed to disclose a material fact required to be disclosed to such governmental authority. All material reports, documents, claims and notices required or
requested to be filed, maintained or furnished under any applicable regulatory law by Company, have been so filed, maintained or furnished and were complete and correct in all material respects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Representations and Warranties of the Purchaser</U>. The Purchaser hereby represents
and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Organization; Authority</U>. The Purchaser is an entity duly incorporated or formed, validly existing and in good standing under the
laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by this Agreement and
otherwise to carry out its obligations hereunder. The execution and delivery of this Agreement and performance by the Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the
part of the Purchaser. This Agreement has been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of the Purchaser, enforceable against it
in accordance with its terms, except: (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#146; rights
generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Understandings or Arrangements</U>. The Purchaser is acquiring the Purchased Shares as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Purchased Shares (this representation and warranty not limiting the Purchaser&#146;s right to sell the Purchased Shares in
compliance with applicable federal and state securities laws). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Experience of the Purchaser</U>. The Purchaser, either alone or
together with its Representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Purchased Shares, and has so evaluated
the merits and risks of such investment. The Purchaser is able to bear the economic risk of an investment in the Purchased Shares and, at the present time, is able to afford a complete loss of such investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Access to Information</U>. The Purchaser acknowledges that it has had the opportunity to review this Agreement (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded, (i)&nbsp;the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, Representatives of the Company concerning the terms and conditions of the
offering of the Purchased Shares and the merits and risks of investing in the Purchased Shares; (ii)&nbsp;access to information about the Company and its financial condition, results of operations, business, properties, management and prospects
sufficient to enable it to evaluate its investment; and (iii)&nbsp;the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed
investment decision with respect to the investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Certain Transactions and Confidentiality</U>. Other than consummating the
transactions contemplated hereunder, the Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with the Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities
of the Company during the period commencing as of the time that the Purchaser first received a preliminary term sheet (written or oral) from the Company or any other Person representing the Company setting forth the proposed terms of the
transactions contemplated hereunder and ending immediately prior to the execution hereof. Other than to the Purchaser&#146;s Representatives, including, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, the Purchaser has maintained the confidentiality of all disclosures made to it
in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company
acknowledges and agrees that the representations contained in this <U>Section</U><U></U><U>&nbsp;3.2</U> shall not modify, amend or affect the Purchaser&#146;s right to rely on the Company&#146;s representations and warranties contained in this
Agreement or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OTHER
AGREEMENTS OF THE PARTIES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise
negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Purchased Shares for purposes of the rules and regulations of any Trading Market such that it would
require shareholder approval prior to the Closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Securities Laws Disclosure; Publicity</U>. The Company shall (a)&nbsp;by the Disclosure Time, issue a press release disclosing the
material terms of the transactions contemplated hereby, and (b)&nbsp;file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> including this Agreement as an exhibit thereto, with the Commission within the time required by the
Exchange Act, in each case in the form mutually agreed to by the Company and the Purchaser. At any time up to the Closing Date, the Company and the Purchaser shall consult with each other in issuing any other press releases with respect to the
transactions contemplated hereby, and neither the Company nor the Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of the Purchaser,
or without the prior consent of the Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall
promptly provide the other party with prior notice of such public statement or communication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Use of Proceeds</U>. The Company
will use the net proceeds as described in the Prospectus Supplement under the section entitled &#147;Use of Proceeds.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4
<U>Listing of Common Shares</U>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of the Common Shares on the Trading Market on which it is currently listed. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MISCELLANEOUS
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Fees and Expenses</U>. At the Closing, the Company shall reimburse Purchaser for all reasonable and documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses (up to a maximum of $150,000 for all such reasonable and documented
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses), including without limitation with respect to Purchaser&#146;s advisors, legal counsel, accountants and other experts, if any, and all
other reasonable and documented expenses incurred by Purchaser incident to the negotiation, preparation and execution, of this Agreement and the transactions contemplated hereby. The Company shall pay all Transfer Agent fees, stamp taxes and other
taxes and duties levied in connection with the delivery of the Purchased Shares to the Purchaser.<U> </U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Entire Agreement</U>. This Agreement contains the entire understanding of the parties
with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the
signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b)&nbsp;the next Trading Day after the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email
attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c)&nbsp;the second (2nd) Trading Day following the date of
mailing, if sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature
pages attached hereto. To the extent that any notice provided pursuant to this Agreement constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company, the Company shall simultaneously file
such notice with the Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchaser, and in the case of a waiver, by the party against whom
enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a
waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any amendment effected in accordance with this
<U>Section</U><U></U><U>&nbsp;5.4</U> shall be binding upon the Purchaser and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Headings</U>. The headings herein are
for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party (other than by merger). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>No Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective successors and
permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>Governing Law</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective Affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York, borough of Manhattan. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
York, borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the
enforcement of this Agreement), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is
an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of this Agreement, then the prevailing party in such Action or
Proceeding shall be reimbursed by the <FONT STYLE="white-space:nowrap">non-prevailing</FONT> party for its reasonable attorneys&#146; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or
Proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be
considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. Counterparts may be
delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal <FONT STYLE="white-space:nowrap">E-SIGN</FONT> Act of 2000, <I>e.g.</I>, www.docusign.com) or other transmission method and any
counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10
<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set
forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or
substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and
restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Purchaser and the Company will be entitled to specific performance under this Agreement. The parties agree that monetary
damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in this Agreement and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense
that a remedy at law would be adequate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12 <U>Saturdays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any
action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13 <U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
this Agreement and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement or any amendments thereto. In addition,
each and every reference to share prices and shares of common stock in this Agreement shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the common stock that
occur after the date of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.14 <B><U>WAIVER OF JURY TRIAL</U></B><B>. </B><B><U>IN ANY ACTION, SUIT, OR PROCEEDING IN
ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY
JURY. </U></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Signature Pages Follow</I>) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be
duly executed by their respective authorized signatories as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ORIC PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jacob M. Chacko, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Jacob M. Chacko, M.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:
President and Chief Executive Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address for Notices:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORIC
Pharmaceuticals, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">240 E. Grand Ave, 2nd Floor</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">South San
Francisco, CA 94080</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">With copies (which shall not constitute notice) to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">650 Page Mill Rd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94304</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Jennifer Knapp</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: jknapp@wsgr.com</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Securities Purchase Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be
duly executed by their respective authorized signatories as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PURCHASER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PFIZER INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ John DeYoung</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">John DeYoung</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Worldwide Business Development</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">235 East 42nd Street New York, NY 10017</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: John DeYoung</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: [***]</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: [***]</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With a copy to: 235 East 42nd Street<BR>New York, NY 10017</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Andrew J. Muratore</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: [***]</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: [***]</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Securities Purchase Agreement] </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>oric-20221221.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/22/2022 3:20:52 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:oric="http://www.oricpharma.com/20221221"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.oricpharma.com/20221221"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oric-20221221_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oric-20221221_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>oric-20221221_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/22/2022 3:20:52 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>oric-20221221_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/22/2022 3:20:52 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="oric-20221221.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g399008g1221133513609.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g399008g1221133513609.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P ( # 2(  A$! Q$!_\0
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,3_Y>(G5X=_UU/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g399008g1221134219834.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g399008g1221134219834.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  8 $ # 2(  A$! Q$!_\0
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MI7$\BZA%'=:;>HS9'SCS(F;KD=1]?<5['H[^&K6XO/"NEB&&:V0&XM5#!B&
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3\)-P#BBBFGM\B;6N_P#%^9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140256215071008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001796280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 21,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ORIC Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1787157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">240 E. Grand Ave<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">388-5600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ORIC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>d399008d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="oric-20221221.xsd" xlink:type="simple"/>
    <context id="duration_2022-12-21_to_2022-12-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <startDate>2022-12-21</startDate>
            <endDate>2022-12-21</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-12-21_to_2022-12-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-12-21_to_2022-12-21"
      id="Hidden_dei_EntityCentralIndexKey">0001796280</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-12-21_to_2022-12-21">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-12-21_to_2022-12-21">2022-12-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-12-21_to_2022-12-21">ORIC Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-12-21_to_2022-12-21">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-12-21_to_2022-12-21">001-39269</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-12-21_to_2022-12-21">47-1787157</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-12-21_to_2022-12-21">240 E. Grand Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-12-21_to_2022-12-21">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-12-21_to_2022-12-21">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-12-21_to_2022-12-21">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-12-21_to_2022-12-21">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-12-21_to_2022-12-21">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-12-21_to_2022-12-21">388-5600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-12-21_to_2022-12-21">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-12-21_to_2022-12-21">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-12-21_to_2022-12-21">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-12-21_to_2022-12-21">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-12-21_to_2022-12-21">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-12-21_to_2022-12-21">ORIC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-12-21_to_2022-12-21">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-12-21_to_2022-12-21">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2022-12-21_to_2022-12-21">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MY?X^;M\_ D[MF51D*??US1.76\#&:4L6+"$SB&,@=" QS*HY^!=UAQ*S6+S
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    "  PBY5599!YDAD!  #/ P  $P
M %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C
M3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=
M(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B
M63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.Q
MD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[
MV?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D
M@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( #"+
ME54'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N
M>&UL4$L! A0#%     @ ,(N558Q ]4'M    *P(  !$              ( !
MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ,(N559E<G",0!@
MG"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  PBY55<"7P<8<$  #5$0  &               @($,"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ,(N559^@&_"Q @
MX@P   T              ( !R0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  PBY55EXJ[',     3 @  "P              @ &E#P  7W)E;',O+G)E
M;'-02P$"% ,4    "  PBY55'#AEZC\!   \ @  #P              @ &.
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ,(N5520>FZ*M    ^ $
M !H              ( !^A$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ ,(N55660>9(9 0  SP,  !,              ( !WQ(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  *10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d399008d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d399008d8k.htm">d399008d8k.htm</File>
    <File>d399008dex51.htm</File>
    <File>d399008dex991.htm</File>
    <File>d399008dex992.htm</File>
    <File>oric-20221221.xsd</File>
    <File>oric-20221221_lab.xml</File>
    <File>oric-20221221_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d399008d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d399008d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "oric-20221221_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "oric-20221221_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "oric-20221221.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "oric",
   "nsuri": "http://www.oricpharma.com/20221221",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d399008d8k.htm",
      "contextRef": "duration_2022-12-21_to_2022-12-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d399008d8k.htm",
      "contextRef": "duration_2022-12-21_to_2022-12-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20221221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-22-310169-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-310169-xbrl.zip
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MI#X3D?*F1('R4,.I7L$.$ - E_$3A5DZE>F-8![@)W\:MPV%!T#B.$SY< Q
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MZKF.)7=%X@L?7MY)BL+[XL>6M],Q-!VH9SM&_IO2Z]*69&H&9]:VO3CUA$]
M%P!$,SN5M99?;'7=TJR#L;W36GV@E<KVAX?@T@CT,83SJ4@"*LD#]2)&OJ^6
M\78A"? :XBBW5NZ%:KV6H<*J"".A.]4]?_%;C*D=.XN[5'@O^/$HG7%A)%ZV
MN*3*I7^1]YX [QY<-P^<-_*1RD\LS$70<[F9?=]%SYN1P90X^H0"9OP$ LUT
M&=C<L0!7!%QG\-YQT7MR+\5C.$('/L"C JJ(RX;<-\7A)L-:;<5.Z5QZU=PR
M:9 #I/+QJ<ZRQIVY+BL/L*P<3[<VC +J@U*2UEI<,^^*R_I)8^@P(EB8/P5F
M^4F/* OGO7R4&PFQ<K*Z.B&>X;V>H&O&/TFX>I03KCXI<OK#%5R))\JY+,X7
M#KU&P,!:,(&!?:%CK$@QW0M09(_6\*T/7!]RF:O8B!*]EC?%Q1\Y+(W"X -\
MT"+9 U<P#L0""UI ]JGC8!4V=L;W/[A4NLH<JKDK [S& 4T"O#0SE[=A@LE=
M K^Y"_4R'#!'WNT.G;^V6^7FY-F>/W_[#5BZ/$FIL?&"I.!7*7=JP( XX$YY
MCW2J"N8J$;X*)'&](!(7LO-=6_]W&F\HF&02<A4+Q.JS_?V^*N#;;Q92CC]=
MW;SMW92Z5Q\^7%S?]CKQAR\[Y5BKY284B?X(C+28*5LLK.^';&RXXZ1<K95S
M;@&D9WNI_-^JR,!L\TI[$#V\HZG*9)L$VM$^K,*53^(+F0:;\:W,(EE^'8\<
MH'K%\J1Z];0;&UEXJIT>$LWZVKD!Y4R)FCD7H+5!(8.MH/>2Z>1F9J*4&W(=
M][R(>R;3:]-Q/83M20O+Y7^ \<GUN]YAQBZ8: OGMQ!JRZ67-K4?P,]%@H6O
MZ=FR?6*(BZ15;!P?%1O-IHE(5&QC4KO7I5I.)J9)(IDDMDEBFF)V[WK29),T
M!,P%8!)T(/M]LWS42H]$8PKV6VF+Z "L&AQ=,#/A>.CI3<GW]5:Y:D@*E/?0
M%*<7U!:.6LMI5BV;^\YF>X] 0RQ8M*0$<%+Y59=+IOU#:$8+#<;1C;1#@-01
M48B>ALXO/P)! 6Z -_"H26@#>O6_?M:,HV\"\SFZ4E*-F#>[4ZG]"'V12H^'
MA\W*?VY+C=@33:KJ]%QK1UX*ZR\T&HU2O=4Z:322O'D:BYE9;V,(8X0:[D)"
M"KP0&D:*J"@(/+,-R3RJ_1O8/$ZIL:E'*&HR=&&*',"60^Y9#"_UVF?W'K+<
MU>MFB9RB/D8K;!(8?PY <3P!<H?E3@#, &DYIQ\:L7Y0T>!/9 ,<% '#@RJ:
MZN$Q2V@'"I3:!3P%28U4H$MD8?=,JP+?!S_/T7A8!&P829\#,[@8-?4F(S[@
M(6FWRS6#-.C1C:1$;-K;[QOS1JHT+*/,,M/-D+;<-S>7^#]7#=^EU)1C8  9
M-J5J*NUB^RR<"?U0BO$"VJ#S$&0/4'$O=($H"IH'> 8L.N"CH1X'!YUK;3ZK
M(U4A_#5Z;2WRT#*46HU&,4;A9B-JM68\ (':;%"[V2RF1Z'N>Q3RDV8R&O 0
M@P7X_MX6V,47H!AJEP!X63T/]21#Q@:ZF0.Z(HBLQ'@)<8KP.0),/#PK'4K0
M./Z?D^1%PV<T\9BZ#'UCU.R( 1PV@!T/>9C(%95Z"O0GF%:H+@R;0K>TI'I\
MS"V(L9V+ N":@:EZ1-@D,A*6,)H)07XA%I/()![$B>L!UC66"1E<@O!PO4+R
M&C-@3M@(&E@3T<& !P8J1"JCW[B?O#(0K0#5J^NEP9J,54[B(@<.1( -4)<L
MHRLWM?\UA#U'P#W+%XZE$Y"/%_H'$:@Y746L-388/<]%5(,'K.D*B/P3])J>
M*%'9+E>H'R/4Z);V\_Z#"9<A*#5ER(9W+(RZ(E6E+$"O^SR\C0&3428N4X[D
M0;H>=BTS( UTZ,]"IK<#W_T%R,Z\( %O9 ';3K-L8DWC,/(\G<W<:$T@26)P
MC!/(8^.9M2+U95;$ IGAX@Q<AJ6?'OE9RRD"T-X&\;]Q3Z'+ 6(,WY'W0KC@
M+8YLDH..@U.8 LN9B^1:BB'3/@'P=W=V/73! ?& WST>)LN!(Q'AFS>7^20I
M[S#'=-,PI,Z<Y6Z!X4YIIY4HUN$#SIOO8ZW$_5/<=\@+2/7G#IH@[A3.P?$
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MM%=N&HJ<5<QO_NI?!#[_/U!+ P04    "  PBY55#[5 IB(*  ":)P  $
M &0S.3DP,#AD97@U,2YH=&WM&FMOVLCV.Q+_8<3>KM*5(;R2)H0@.>" ;QU
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ME0B/\-/MYYC849@TA&:E-_P1?_]03O%J=[>;XR 5,93[@B>NI#;>4],EX4@
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M<MO8DB[Z7Q%Z!T3U$%('K))DNP;+[;BT))?5VY9T)7E7USUQ?H D**%, MP
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MPR=@JCF4=H@WUF3"*$/@$OU(KR].B-)])!EK[^PK9K*))8YTA\/[*T8G.:$
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M,:.:W!JQM.()X'%W#":U6^PR<&9<S6O*A5$W(Y2B\!L;3X:ATYI4X5'D;O-
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MA7*LG-/Y[FXTP;-?-+7*<!PO8N'5@(\!J 78L4]$IIE?%\&3&S"T;KP9;*?
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M"YJ3KCV\;QCQ>G#P/:C_V<R\>RZH2$NZ)5^EIF*F7Q;OV;/@TDY01*YF.G7
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MTL0/YN,SMP-MOA(8B .*42F'6_,D$EKW+@X((5B;YQKGUEWY1R]R32F:DY"
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M$=B3B73E?12196_L3,1NZF&_B/UBD_?[.__1&5@_U#[^ Q]_^F:G^.\,A7_
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MVXQK=[N2=0>9K9_D=J=_XINM9N+0ZQ]02P,$%     @ ,(N551UEKB&H!@
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MPJ%.H2.,+4SQ0Y$N6!]21<);E8%R'<@*05K)&?2V392!?Z835/0OI5P1X3X
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M#)AHMW%1WG&EMO1O%\IWT>QW[*@]_P-02P,$%     @ ,(N557N!SSW8!
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M/?;%WHJ+6_X&4$L! A0#%     @ ,(N55<",)J9(%   >'L   X
M     ( !     &0S.3DP,#AD.&LN:'1M4$L! A0#%     @ ,(N550^U0*8B
M"@  FB<  !               ( !=!0  &0S.3DP,#AD97@U,2YH=&U02P$"
M% ,4    "  PBY55 L6\:-@0  "N-@  $0              @ '$'@  9#,Y
M.3 P.&1E>#DY,2YH=&U02P$"% ,4    "  PBY55",+L,5Y@  "[O@$ $0
M            @ '++P  9#,Y.3 P.&1E>#DY,BYH=&U02P$"% ,4    "  P
MBY55E^6&M3@#  !3"P  $0              @ %8D   ;W)I8RTR,#(R,3(R
M,2YX<V102P$"% ,4    "  PBY55'66N(:@&  "E20  %0
M@ &_DP  ;W)I8RTR,#(R,3(R,5]L86(N>&UL4$L! A0#%     @ ,(N557N!
MSSW8!   !"X  !4              ( !FIH  &]R:6,M,C R,C$R,C%?<')E
:+GAM;%!+!08     !P ' +T!  "EGP     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
